PDCD1 and gastric cancer: A recent trial (NCT04264975) examined the combined therapeutic effect of anti-PD-1 and FMT on 13 non-responders to anti-PD-(L)1 therapy with advanced solid tumors, including GC, HCC, or esophageal squamous cell carcinoma (58).